Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

An Auckland-based artist living with debilitating symptoms of topical steroid withdrawal (TSW) believes his dermatologists ...

There are several effective self-care methods and natural home remedies available for relieving headaches without medication.

Nektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR) conference, being held in ...

Senior metals columnist who previously covered industrial metals markets for Metals Week and was EMEA commodities editor at Knight-Ridder (subsequently Bridge). Started up Metals Insider in 2003 ...